0001832511-25-000025
SEC filingP3 Health Partners' Q3 2025 results reflect a strategic contraction with a 5% revenue decline driven by the termination of underperforming contracts, partially offset by a significant reduction in operating loss due to a premium deficiency reserve benefit.
For the three months ended September 30, 2025, P3 Health Partners reported a net loss of $69.5 million, a significant improvement from the $102.9 million loss in the prior year period. This improvement was achieved despite a 5% decline in total operating revenue to $345.3 million, down from $362.1 million. The revenue contraction was primarily driven by a 10% decrease in average at-risk members, falling from 128,400 to 115,900, as management strategically terminated underperforming payor contracts and affiliate providers. Capitated revenue, which constitutes 99% of total revenue, decreased by $16.2 million to $341.6 million.
The most significant factor in the reduced net loss was a $23.7 million benefit from the premium deficiency reserve (PDR), a stark contrast to the $18.2 million expense recorded in Q3 2024. This $41.9 million swing reflects management's assessment that the maturation of contractual arrangements is expected to reduce future losses. Operating loss consequently narrowed to $44.2 million from $107.0 million. Medical expense decreased 8% to $369.8 million, in line with the smaller membership base, while corporate, general and administrative expenses fell 19% to $22.1 million, driven by headcount reductions and the sale of the company's Florida operations.
The company operates a single reportable segment focused on population health management for Medicare Advantage members. Within this, capitated revenue is the dominant component, representing 99% of total operating revenue. The 5% decline in this revenue stream is a direct result of a deliberate strategic shift to exit unprofitable contracts, which reduced the at-risk member count. This is further evidenced by a decrease in the affiliate primary care physician network from 3,100 to 2,700 physicians. Other patient service revenue, a minor component at 1% of total revenue, also declined by 16% to $3.7 million. The core dynamic is a trade-off between top-line scale and bottom-line performance, with the current strategy prioritizing the latter by shedding loss-generating contracts.
Management's outlook is dominated by a going concern warning. The company explicitly states that existing cash resources are not sufficient to support planned operations for at least the next year, raising substantial doubt about its ability to continue. To address this, P3 is actively exploring raising additional capital through debt and equity financing. The company has recently relied on high-interest promissory notes, such as the VGS 4 and VGS 5 facilities carrying a 19.5% annual interest rate, to fund operations. Future capital requirements will depend on the pace of growth, ability to manage medical costs, and success in refinancing maturing indebtedness. The strategic focus remains on improving contract profitability and achieving operating efficiencies, but the immediate priority is securing the financing necessary to sustain operations.
As of September 30, 2025, P3 Health Partners Inc. reported unrestricted cash and cash equivalents of $37.7 million, a slight decrease from $38.8 million at December 31, 2024. The Company's working capital deficit stood at $288.3 million, driven by current liabilities of $424.0 million against current assets of $135.6 million. Total stockholders' equity shifted to a deficit of $18.7 million from a positive $75.9 million at year-end 2024, primarily due to an accumulated deficit of $575.6 million. The accompanying notes explicitly state that substantial doubt exists about the Company's ability to continue as a going concern within one year after the financial statement issuance date, citing recurring losses and adverse claims experience.
The Notes section does not disclose a specific purchase commitments table or aggregate contractual obligations figure. However, significant financing commitments are detailed. The Company entered into multiple related-party promissory notes (VGS 4 and VGS 5) with VBC Growth SPV entities, providing for up to $100.0 million in additional funding, of which $70.0 million was drawn as of September 30, 2025. An additional $13.0 million was drawn on October 7, 2025. These notes carry a 19.5% per annum interest rate and mature in 2028. The Term Loan Agreement was amended (Tenth Amendment) to extend the interest-only period to June 30, 2026 and the final maturity to September 30, 2027, with the interest rate increasing to 15% after September 30, 2025.
Gross long-term debt increased significantly to $312.2 million from $198.0 million at year-end, with net long-term debt of $214.2 million after unamortized debt issuance costs and original issue discounts of $59.5 million. The Company issued $60.0 million in new long-term debt, net of discount, and $1.1 million in short-term debt, while repaying $1.0 million. No share buybacks or dividends were disclosed. Capital expenditures were minimal at $0.1 million for the nine months ended September 30, 2025. The Company issued warrants to purchase 1.4 million shares of Class A common stock in connection with each of the VGS 4 and VGS 5 financings.
The Company operates under a single reportable segment. Capitated revenue accounted for 98.9% of total operating revenue for both the three and nine months ended September 30, 2025. Customer concentration is high, with five health plan customers each accounting for 10% or more of total revenue, collectively comprising 75% of total revenue for the nine-month period. No geographic revenue mix is disclosed at the segment level.
P3 Health Partners Inc. continues to experience significant cash consumption, with net cash used in operating activities of $65.5 million for the nine months ended September 30, 2025, a 24% increase from the $52.9 million used in the prior year period. This operating cash outflow substantially exceeds the reported net loss of $157.4 million, primarily due to non-cash adjustments including $63.2 million in depreciation and amortization and a $36.7 million benefit from a premium deficiency reserve release. However, working capital movements tell a mixed story: a $39.2 million decrease in health plan receivables provided a significant source of cash, while a $12.3 million increase in other long-term assets and a $1.4 million decrease in claims payable consumed cash. Notably, claims payable increased by $52.7 million in the prior year period, representing a dramatic swing in medical claims liability management.
Capital expenditures are negligible at $0.1 million, indicating minimal investment in property and equipment. Consequently, free cash flow is approximately negative $65.6 million, mirroring the operating cash outflow. The company has no share repurchases or dividends, relying entirely on external financing to fund operations. Financing activities generated $59.9 million, predominantly from $60.0 million in long-term debt proceeds, net of discount. This debt dependency, combined with a working capital deficit of $288.3 million and substantial doubt about the company's ability to continue as a going concern, underscores severe liquidity risk. The cash balance declined from $44.1 million to $38.5 million over the period, with restricted cash comprising only $0.7 million of the ending balance.